• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Promise Bio Secures $8.3M for Auto-Immune Precision Medicine Platform

by Syed Hamza Sohail 12/16/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment.

– This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.

Revolutionizing Immune-Mediated Disease Management through Epiproteomics and AI

Promise Bio is a trailblazer in precision medicine, advancing the management of immune-mediated diseases with an innovative focus on epiproteomics and artificial intelligence (AI). Leveraging groundbreaking research from the Weizmann Institute of Science, the company’s proprietary technology enables large-scale profiling of post-translational modifications (PTMs) in proteins. This platform identifies disease mechanisms, customizes therapies, and uncovers novel drug targets with unparalleled precision.

At the core of Promise Bio’s success is its proprietary PROMISE (Protein Modification Integrated Search Engine) platform, developed by Co-Founder & CTO Dr. Assaf Kacen. This cutting-edge system, based on foundational research conducted in Prof. Yifat Merbl’s lab at the Weizmann Institute and published in Nature Biotechnology in 2023, allows high-throughput profiling of dozens of PTMs using mass spectrometry. The platform eliminates the need for customized chemical enrichment or additional lab procedures, significantly streamlining the analysis of PTMs and accelerating biomedical discovery.

Strategic partnerships with two leading biopharmaceutical companies enhance Promise Bio’s capacity to integrate its technology into global drug development pipelines. These alliances provide:

  • Financial support, ensuring sustained innovation.
  • Industry expertise, enabling effective translation of research into clinical applications.
  • Access to global networks, fostering collaboration and expanding the reach of precision medicine solutions.

By building the world’s largest PTM database, Promise Bio is creating an indispensable resource for medical breakthroughs while addressing pressing clinical challenges in immune-mediated diseases.

Addressing the unmet need for precision treatments, Promise Bio targets the current inefficiencies in autoimmune disease therapies, where only 30–40% of patients achieve significant remission. The company emphasizes data-driven approaches to eliminate the trial-and-error treatment paradigm. Its PROMISE platform focuses not only on protein levels but also on the modifications proteins undergo after formation, delivering actionable insights for tailored interventions.

“Proteins are the building blocks of the human body, and understanding their post-formation changes is key to solving the challenges in immune-mediated diseases,” explained Ronel Veksler, Co-Founder & CEO. With this vision, Promise Bio is poised to transform the future of precision medicine.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |